Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. iRhythm Holdings's annualized ROCE % for the quarter that ended in Jun. 2026 was 0.96%.
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
iRhythm Holdings ROCE % Related Terms
iRhythm Holdings ROCE % Historical Data
* Premium members only.
The historical data trend for iRhythm Holdings's ROCE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
(1) Note:
The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
iRhythm Holdings (IRTC) has a ROCE % of 0.96% as of Jun. 2026.
Is iRhythm Holdings' ROCE % too high?
iRhythm Holdings' current ROCE % is 0.96%. The Medical Devices & Instruments industry median ROCE % is 2.40. iRhythm Holdings' value of 0.96% is 59.9% below this industry median. Overall, iRhythm Holdings has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does iRhythm Holdings' ROCE % compare to HAE and ITGR?
iRhythm Holdings' ROCE % of 0.96% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.40. iRhythm Holdings' value of 0.96% is 59.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.40, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. iRhythm Holdings's current ROCE % of 0.96% is 59.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. iRhythm Holdings's current ROCE % is 0.96%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iRhythm Holdings stock overvalued right now?
Based on GuruFocus' analysis, iRhythm Holdings (IRTC) is currently considered Modestly Undervalued. The stock's GF Value™ is $154.46, compared to a current price of $127.84 — trading 17.2% below its estimated fair value. The current ROCE % is 0.96% and 59.9% below the Medical Devices & Instruments industry median of 2.40. iRhythm Holdings' overall GF Score™ is 79/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For iRhythm Holdings (IRTC), the current ROCE % is 0.96% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is iRhythm Holdings (IRTC) Overvalued in 2026?
Based on GuruFocus' analysis, iRhythm Holdings stock appears to be undervalued.
The current stock price of $127.84 is trading 17.2% below its estimated GF Value™ of $154.46.
GuruFocus considers iRhythm Holdings to be Modestly Undervalued.
Key valuation signals for IRTC:
ROCE %: 0.96%
GF Value™: $154.46 vs. price of $127.84 (17.2% below fair value)
Industry Position: 59.9% below the Medical Devices & Instruments median
No single metric tells the full story. See the IRTC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
79GF Score
Get the complete analysis for IRTC
ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IRTC has been successfully added to your 
